On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease. FDA Approves Oral Breast Cancer Combination Wilserdly The FDA approved Wilserdly (giredestrant) plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or...
Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies
On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments ac...
By Dhallo News · November 18, 2026 at 12:19 AM IST
Have feedback on this article?Report error or suggestion
